Cannabis Law Report

NOVEMBER 12, 2021

The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. In compliance with current Good Manufacturing Practice requirements, the Company delivered ANEB-001’s active pharmaceutical ingredient to its contract manufacturer to fill into 10 mg and 50 mg capsules for finished product. June 30, 2021. .

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Cannabis Law Report

JUNE 2, 2021

The Company is offering pooled surveillance testing in compliance with current CDC, FDA, and CMS guidances. FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration (U.S.

Clinical Trials 63

Clinical Trials Therapy Collective Research and Development 63

Cannabis Law Report

OCTOBER 26, 2019

ii Non-clinical studiesAlthough the use of animals in research is separately regulated by each state and territory, all require compliance with the Australian Code for the Care and Use of Animals for Scientific Purposes (Animal Code). One such circumstance is a clinical trial. medical practitioner), an organisation (e.g.,

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

DECEMBER 9, 2021

These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU.

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 40

Clinical Trials Research and Development Data Medicine 40

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. .

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC is a Public Benefit Corporation, with a dual mandate to generate shareholder value and public benefit. Minimum Requirements.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease. March 31, 2021. ($). .

Clinical Trials 40

Clinical Trials Research and Development Data Business 40

Cannabis Law Report

DECEMBER 21, 2021

The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion in 2020 (Grandview Research). from 2021 to 2028.

Research and Development 40

Research and Development Supply Chain Data Business 40

Cannabis Law Report

JULY 24, 2019

FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance, 10903 New Hampshire Avenue, WO51, Silver Spring, MD 20993-0002 or by email to FDAADVISORY@fda.hhs.gov. 331(d) and 355(a).

CBD 51

CBD Tincture Pets Chronic Pain 51

Cannabis Law Report

JUNE 1, 2021

Over the course of her career, she has established, developed, and led several key areas of human resource functions including communications and strategy, talent engagement and management, compliance, and mergers and acquisitions.

Research and Development 51

Research and Development Treatment Pharmaceutical Patients 51

Cannabis Law Report

MAY 29, 2022

Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JUNE 3, 2022

Develop, implement, and maintain written policies, procedures, and guidelines to facilitate compliance with federal, state, and local laws, regulations, and rules, and industry standards. Manage compliance matters handled by outside counsel and consultants. Handle other compliance matters as assigned by the General Counsel.

Legalization 59

Legalization Clinical Trials Compliance Compliance 59

Cannabis Law Report

JULY 21, 2022

Patient safety concerns uncovered during an ongoing federal review have led to the suspension of one of two clinical trials for MDMA-assisted psychotherapy currently underway in Canada. ” The complaint alleges that MAPS improperly blended data from small study sites that used different methodologies to produce favourable results.

Safety 52

Safety Patients Clinical Trials Data 52

Cannabis Law Report

MARCH 1, 2022

Develop, implement, and maintain written policies, procedures, and guidelines to facilitate compliance with federal, state, and local laws, regulations, and rules, and industry standards. Manage compliance matters handled by outside counsel and consultants. Handle other compliance matters as assigned by the General Counsel.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

OCTOBER 2, 2021

Develop, implement, and maintain written policies, procedures, and guidelines to facilitate compliance with federal, state, and local laws, regulations, and rules, and industry standards. Manage compliance matters handled by outside counsel and consultants. Handle other compliance matters as assigned by the General Counsel.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52

Cannabis Law Report

OCTOBER 17, 2019

Another researcher, New Frontier Data, pegged the global value of legal and illicit cannabis together at $340 billion in 2018. By passing the Cannabis Act, Canada has taken a position of principled non-compliance with its international drug treaty obligations,” says Fraser. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40